RxDoctor Payments Data

Darryl Morin, MD

Internal Medicine · Mobile, ALNPI 1083892285

Payments from drug & device makers

$5,038in general payments, 2019–2025

Across 270 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$442
  • Amarin Pharma, Inc.$391
  • Medtronic$333
  • E.r. Squibb & Sons, L.L.C.$257
  • Pfizer$244
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,016100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,038 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$17,126
Medicare patients
62
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$46,821
EliquisApixaban30$39,646
MounjaroTirzepatide27$27,570
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$20,270
TrulicityDulaglutide16$19,342
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,954
Albuterol Sulfate HfaAlbuterol Sulfate74$2,705
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,430
Atorvastatin Calcium231$2,250
Gabapentin95$1,383
Omeprazole96$1,350
Famotidine56$1,330
Losartan Potassium115$1,238
Levothyroxine Sodium117$1,184
Pantoprazole Sodium101$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$27$46,91143 claims
Novo NordiskOzempic$220$46,82143 claims
PfizerEliquis$244$39,64630 claims
GSKTrelegy Ellipta$110$20,27025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →